A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), has come up with a treatment for Covid. Just spare a few minutes to know more about it…..
Transcell Oncologics claims of breakthrough
Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
The bio-tech announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
Inflammatory cytokines
The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the Covid-19 ‘cytokine storm’, with significantly improved patient survival and time to recovery.
The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the Covid patients”.
Read this also Ten Key points that every start-up founder should know before starting his venture
Helpful for Covid patients
Subadra Dravida, Founder CEO, Transcell, said, “The advantage of the therapy is this new way of curing covid patients in real time to SAVE them and NOT to treat the symptoms alone.”
“Also, if HEMATO UC-MSCs are administered as the first line of treatment followed by concomitant steps to alleviate the associated symptoms in a traditional way, Covid deaths can be dodged”.
Representational photo
Speedy delivery
HEMATO UC-MSCs can be delivered pan India within 48 hours and have been specially treated for storage under 2-8-degree Celsius refrigerated conditions for of use by the practitioners within 72 hours.
Got the confirmation
The effectiveness of this MSC based technology has been confirmed by the Cell Transplant Centre, Miami Miller School of Medicine, Jackson Health System, Department of Public Health Sciences, USA, on Covid-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS).
It has released a detailed research paper on a randomised controlled trial and confirmed the laboratory findings from Transcell Oncologics.
Keywords: chalgenius, start-ups, Hyderabad, University, atmanirbhar bharat, vocalforlocal, ARDS, Transcell Oncologics
Follow us on Facebook, Linkedin and Instagram to get timely updates about start-ups
What kind articles you want to see in our website. Please mail us at gurvinder@chalgenius.com
You also want to feature your start-ups here. No Worries. Call or whatsapp at 8910430165. Please click to know more about us
Chalgenius is not just a media site. It creates more business opportunities for you by connecting you with thousands of potential customers, investors, accelerators and mentors across the country. Come grow your business with us. Contact us at 8910430165 or mail at chalgeniusss@gmail.com for further details.
Please subscribe our YouTube channel and like our Facebook page to know more about such inspiring startups.
Get more stuff like this
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.
Thank you for subscribing.
Something went wrong.
